Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 22

Texture Analysis of 68GaDOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors

Objectives: The aim of our study is to evaluate whether texture analysis of 68Ga-DOTATOC PET/CT images can predict clinical outcome in patients with neuroendocrine tumors (NET). Methods: Forty-seven NET patients who had undergone 68Ga-DOTATOC PET/CT were studied. Primary tumors were localized in the gastroenteropancreatic (n = 35), bronchopulmonary (n = 8), and other (n = 4) districts. NET lesions were segmented using an automated contouring program and subjected to texture analysis, thus obtaining the conventional parameters SUVmax and SUVmean, volumetric parameters of the primary lesion, such as Receptor-Expressing Tumor Volume (RETV) and Total Lesion Receptor Expression (TLRE), volumetric parameters of the lesions in the whole-body, such as wbRETV and wbTLRE, and texture features such as Coefficient of Variation (CoV), HISTO Skewness, HISTO Kurtosis, HISTO Entropy-log10, GLCM Entropy-log10, GLCM Dissimilarity, and NGLDM Coarseness. Patients were subjected to a mean follow-up period of 17 months, and survival analysis was performed using the Kaplan–Meier method and log-rank tests. Results: Forty-seven primary lesions were analyzed. Survival analysis was performed, including clinical variables along with conventional, volumetric, and texture imaging features. At univariate analysis, overall survival (OS) was predicted by age (p = 0.0079), grading (p = 0.0130), SUVmax (p = 0.0017), SUVmean (p = 0.0011), CoV (p = 0.0037), HISTO Entropy-log10 (p = 0.0039), GLCM Entropy-log10 (p = 0.0044), and GLCM Dissimilarity (p = 0.0063). At multivariate analysis, only GLCM Entropy-log10 was retained in the model (χ2 = 7.7120, p = 0.0055). Kaplan–Meier curves showed that patients with GLCM Entropy-log10 >1.28 had a significantly better OS than patients with GLCM Entropy-log10 ≤1.28 (χ2 = 10.6063, p = 0.0011). Conclusions: Texture analysis of 68Ga-DOTATOC PET/CT images, by revealing the heterogeneity of somatostatin receptor expression, can predict the clinical outcome of NET patients.

MicroRNA-based gene therapy to treat ALS

A single IV injection of a microRNA-based biologic suppressed production of the mutant SOD1 protein that causes amyotrophic lateral sclerosis (ALS); delayed disease onset by 60 days; and extended lifespan by 100 days, more than triple the average survival time, in mice models of the disease.

The gene therapy, delivered via adeno-associated virus (AAV) vector, preserved motor neurons and maintained neuromuscular connections in treated animals, which translated into improved muscle and respiratory function, motor performance, and lifespan in pre-clinical studies. These findings, published in Nature Communications, have the potential for clinical application in patients with SOD1-caused ALS, as well as other neurodegenerative diseases caused by toxic, gain-of-function gene mutations.

“These therapeutic benefits, from a single IV injection, are unprecedented among gene therapy approaches in this mouse model,” said the senior author. “No other studies have been able to achieve this kind of survival extension. This makes us very optimistic that our approach could have a meaningful impact for patients suffering from this horrible disease and warrants further clinical evaluation.”

Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment

Resistance to cancer drugs is a complex phenomenon that poses a significant challenge in the treatment of various malignancies. This review comprehensively explores cancer resistance mechanisms and discusses emerging strategies and modalities to overcome this obstacle. Many factors contribute to cancer resistance, including genetic mutations, activation of alternative signaling pathways, and alterations in the tumor microenvironment. Innovative approaches, such as targeted protein degradation, immunotherapy combinations, precision medicine, and novel drug delivery systems, hold promise for improving treatment outcomes. Understanding the intricacies of cancer resistance and leveraging innovative modalities are essential for advancing cancer therapy.

How muscle cells grow and stay healthy

Biophysicists unraveled a mystery of how muscles form at the molecular level and how they maintain their function. Nature Communications published the discovery, which may help in the design of treatments for muscle diseases such as dilated cardiomyopathy, one of the leading causes of heart failure.

“We’ve made a fundamental advance in understanding how the cellular cytoskeleton is assembled, especially in muscle cells,” says the senior author of the study.

The researchers upended a model relied on for more than four decades to explain how filaments of actin, a protein vital to cellular movement and other functions, form and maintain their length.

Cerebral Edema in Traumatic Brain Injury

Cerebral edema is the abnormal accumulation of fluid in any of the tissue compartments of the cerebral parenchyma. It remains a significant challenge in neurotrauma care because it contributes to secondary brain injury, affecting prognosis. This review analyzes the recent literature, including foundational studies, to describe the mechanisms of distinct types of cerebral edema following traumatic brain injury (TBI). Emerging concepts, such as the role of the glymphatic system and heme-derived inflammasomes, offer new insights into new types of edemas, differentiated by pathogenesis and potential treatments. Recent advancements in understanding these molecular mechanisms can improve therapeutic strategies, facilitating a better approach in the era of precision and personalized medicine.

Should Brain MRI Screening Expand in Metastatic Breast Cancer?

Brain metastases are a major clinical concern in metastatic breast cancer, particularly in HER2-positive and triple-negative disease. Over time, approximately 25% to 50% of patients with these subtypes develop brain metastases, which can lead to neurological disability, cognitive impairment, reduced independence, and substantial deterioration in quality of life.

Despite this risk, routine brain imaging is not consistently recommended for patients without neurological symptoms.

An article published in The Breast argues that it may be time to reconsider this symptom-directed approach. Sarah Sammons, Nayan Lamba, and Nancy U. Lin outline a growing case for brain MRI screening in selected patients with metastatic breast cancer, while also acknowledging that survival benefit, optimal timing, cost-effectiveness, and potential harms remain uncertain.

/* */